Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 11/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895303 | 0.94 | FFAR2 (0.48) | FFAR2FBP1CTSLCTSSGCK | |
| SCHEMBL9894828 | 0.93 | FFAR2 (0.45) | FFAR2FBP1CTSLCTSSMAPT | |
| SCHEMBL9894921 | 0.90 | FFAR2 (0.43) | FFAR2FBP1MAPTGCKKDM4E | |
| SCHEMBL9896000 | 0.88 | AKT1 (0.43) | FFAR2FBP1CTSLCTSSMAPT | |
| SCHEMBL9894970 | 0.88 | RORC (0.41) | FFAR2FBP1MAPTGCKKDM4E | |
| SCHEMBL9896462 | 0.88 | MAPT (0.44) | FFAR2FBP1MAPTGCKMEN1 | |
| SCHEMBL9895023 | 0.87 | PTPN1 (0.45) | FFAR2CTSSMAPTGCKMEN1 | |
| SCHEMBL9895818 | 0.87 | PTPN1 (0.45) | FFAR2CTSSMAPTGCKMEN1 | |
| SCHEMBL9894922 | 0.86 | XDH (0.41) | FFAR2FBP1MAPTGCK | |
| SCHEMBL9895191 | 0.86 | GCK (0.40) | FFAR2FBP1CTSLCTSSGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | claimed |
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | P2RX7, P2RX3, P2RX2 | FFAR2 236/4885FBP1 1205/4885CTSL 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.